From the site of the Lombardy Region Ownership of the prestigious research center Nerviano (Nerviano Medical Science, NMS) passes by the Congregation of the Sons of the Immaculate Conception to the regional system. The nerve center, leader in the field of medical and biomedical research, is one of the largest pharmaceutical research and development centers in Italy and one of the major poles of integrated identification and development of cancer drugs in Europe. With these characteristics Excellence is now an integral part of the system of scientic research and Treatment of Lombardy. At the suggestion of President Roberto Formigoni, the council has identified those new owners in Lombardy 4 IRCCS (Research Institutes and by scientific) Hospital, and Besta National Cancer Institute of Milan and San Matteo di Pavia.
This was announced at a press conference the president of the Lombardy Region, Roberto Formigoni, flanked by the Assessor of Health, Luciano Bresciani.
"Our aim - said Formigoni - is to allow you make the most of these centers is to protect and enhance scientific research and pharmacological activities are carried out in it."
This is done at no cost: the passage is free of charge. The jobs of about 600 employees is assured.
"With this initiative - said the president - we wanted to avoid the dissemination of a wealth of knowledge and talent recognized at European level, and even raise our international drug discovery: one area of \u200b\u200bpreclinical research, today made difficulties in both the contraction in investment, both by the tendency of multinationals to concentrate the search in a few countries. "
"This project - pointed out by the Department of Health for its part, Bresciani - shows that our health should not be viewed only as a cost but as a core enabler of growth and development. This is possible thanks to the synergies between the different players: universities, industry and Finlombarda who collaborate with the Region. The full membership of the nerve center in the regional health system is a great event and a great achievement: With regard to oncology, one that is already the biggest platform in the country is strengthened further to study and search for therapies personalizzatre , which represent a significant step forward for medicine. "
Lombardy Region has long been used for the preservation and revitalization of this important Centre. First, assuming a role in directing the complex process that has allowed to" save " NMS endangered by the plans for restructuring pfitzer (then owner of the corporation, after the years of birth in 1965 and then the work of Farmitalia Carlo Erba. So is the experience acquired by the Congregation of the Sons of the Immaculate Conception as well as the subsequent recapitalization (worth 60 million) in 2009 and the launch of a business plan to raise. Relaunch also funding that accompanies the Lombardy Region with 15 million in three years (2010-2012) a major project in connection with the Regional Cancer Network. This funding is intended to achieve in Nerviano of a "virtual bank of biological material," by establishing "a network of bio-banks" in Lombardy. In a biobank are preserved tissue samples used for research of various kinds in the medical field. In this case the constitution of the network of biobanks "will serve to further develop the research for the treatment of cancer through the development of new and more effective drugs. The project is the National Cancer Institute, which triggered a three-year collaboration with the nerve center to complete the program. La Lombarda Oncology Network is a network of Pathology, tried and tested, which binds the structures involved in the research and assistance in this area.
"Through this alliance - said Formigoni yet - so there is the possibility of obtaining a double benefit: is a manufacturing firm as that of Nerviano to a reality of pre-clinical and clinical research that allows you to practice and develop the best possible research and the production of knowledge, and secondly you have the opportunity to test new drugs anti-tumor effects in an appropriate manner, or by a model called 'translational', which requires close integration with a continuous exchange of information between laboratory and clinical activity, important in order to transfer quickly to bedside research results same ".
Now, with the acquisition of property of the Centre, the Lombardy Region is focusing on developing these synergies through the full and effective integration of Nerviano Research Centre of the regional health system in Lombardy. The Center of the rest has all the skills and technologies required for a modern and competitive approach to scientific research on new cancer drugs, with a pipeline of about 12 projects in pre-clinical and clinical development of innovative molecules 5. The direct relationship which is established with the four IRCSS will make the most of the specific functions of scientific research carried out by each of them. And that is the Policlinico S. Matteo di Pavia for the disciplines of transplantation: curable diseases with transplants of organs, tissues and cells and diseases internistic highly complex biomedical and technological research, the "Carlo Besta" in Milan, for diseases nervous system in adults and children, the Hospital of Milan for the repair and replacement of cells, organs and tissues and urgent or emergency in adults and children, and finally the National Cancer Institute for oncology. Not only that: the structure of the Center for Research of Nerviano is perfectly adequate for the implementation of the existing platforms at the foundations of the regional health system, this transaction will allow the creation of a single platform at European level to develop basic research.
Lombardy is the first chemical-pharmaceutical and biotech region in Italy, with more than 100 pharmaceutical companies and 58.5% of clinical trials compared to the national total. In Lombardy, in 2008, been invested in this sector of € 2.5 billion, of which almost 700 million for the acquisition of innovative high-cost medicines in hospitals (cancer drugs, drugs for rare diseases, drugs for HIV patients).
(California News)
Read the original article
0 comments:
Post a Comment